News

Posted: 2010-03-04

Investment recognizes world class oncology research and development expertise at BC Cancer Agency and Vancouver Prostate Centre.

MISSISSAUGA, ONTARIO – AstraZeneca Canada is pleased to announce a $500,000 investment to support oncology research and development at the BC Cancer Agency (BCCA). This adds to the $700,000 Vancouver Prostate Centre investment made in January, and represents a significant collaboration with leading British Columbia breast and prostate cancer researchers.

Posted: 2010-01-25

VANCOUVER, BRITISH COLUMBIA – The Vancouver Prostate Centre announced today an extended collaboration with AstraZeneca that sees the Vancouver Prostate Centre receive $700,000 over two years towards research that targets treatment-resistant prostate cancer.

The research, which is being coordinated through the Vancouver Prostate Centre ― a Centre of Excellence for Commercialization and Research ― evaluates AstraZeneca's androgen receptor-targeting small molecules, as well as, molecules that target cell cycle growth to slow, or stop, tumour proliferation in prostate cancer.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Employment

Work at the Vancouver Prostate Centre

Friday, January 25, 2019

Dr. Wang awarded CIHR project grant; three trainees awarded PCF-BC research grants

Dr. Wang and laboratory
Friday, February 15, 2019

Dr. Zoubeidi interviewed for International Day of Women and Girls in Science

Dr. Amina Zoubeidi